Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 7;9(14):eade4962.
doi: 10.1126/sciadv.ade4962. Epub 2023 Apr 7.

The critical role of engineering in the rapid development of COVID-19 diagnostics: Lessons from the RADx Tech Test Verification Core

Affiliations
Review

The critical role of engineering in the rapid development of COVID-19 diagnostics: Lessons from the RADx Tech Test Verification Core

Robert G Mannino et al. Sci Adv. .

Abstract

Engineering plays a critical role in the development of medical devices, and this has been magnified since 2020 as severe acute respiratory syndrome coronavirus 2 swept over the globe. In response to the coronavirus disease 2019, the National Institutes of Health launched the Rapid Acceleration of Diagnostics (RADx) initiative to help meet the testing needs of the United States and effectively manage the pandemic. As the Engineering and Human Factors team for the RADx Tech Test Verification Core, we directly assessed more than 30 technologies that ultimately contributed to an increase of the country's total testing capacity by 1.7 billion tests to date. In this review, we present central lessons learned from this "apples-to-apples" comparison of novel, rapidly developed diagnostic devices. Overall, the evaluation framework and lessons learned presented in this review may serve as a blueprint for engineers developing point-of-care diagnostics, leaving us better prepared to respond to the next global public health crisis rapidly and effectively.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.. RADx engineering design and human factor readiness and maturity verification process.
Our evaluations focused on the technology, functionality, and manufacturing readiness based on the scale, outcome, and a variety of factors for each parameter.
Fig. 2.
Fig. 2.. Average TRL and usability scores of evaluated technologies.
Evaluated technologies were broadly broken down into the following categories based on the underlying virus detection method: polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), direct antigen detection, and volatile organic compound (VOC) analysis. Both usability scale and TRL are reported on a 1 to 9 scale. A lower usability score indicates as the most usable, and a higher TRL indicates as the most technical maturity. 1 – usability score was used to put highly usable and technologically mature technologies on the same scale.
Fig. 3.
Fig. 3.. Technology breakdown of assessed RADx Tech projects.
Note that some tests can use multiple sample types, so percentages do not add to 100%.
Fig. 4.
Fig. 4.. Sample F&F matrix for usability evaluation.
This homegrown scale enables the assessment of new technology along two usability dimensions: error and efficiency.
Fig. 5.
Fig. 5.. Failure modalities for evaluated technologies.
Failure modalities could be generally categorized into three major groups: poor manufacturability, lack of robust design, and poor usability.

Similar articles

Cited by

References

    1. S. Platto, T. Xue, E. Carafoli, COVID19: An announced pandemic. Cell Death Dis. 11, 799 (2020). - PMC - PubMed
    1. P. E. George, C. L. Stokes, L. C. Bassit, A. Chahroudi, J. Figueroa, M. A. Griffiths, S. Heilman, D. N. Ku, E. J. Nehl, T. Leong, J. M. Levy, R. Kempker, R. G. Mannino, M. Mavigner, S. I. Park, A. Rao, P. A. Rebolledo, J. D. Roback, B. B. Rogers, R. F. Schinazi, J. Sullivan, E. A. Tyburski, M. B. Vos, J. J. Waggoner, Y. F. Wang, J. Madsen, D. S. Wechsler, C. H. Joiner, G. S. Martin, W. A. Lam, Covid-19 will not "magically disappear": Why access to widespread testing is paramount. Am. J. Hematol. 96, 174–178 (2021). - PMC - PubMed
    1. A. S. Fauci, H. C. Lane, R. R. Redfield, Covid-19—Navigating the uncharted. N. Engl. J. Med. 382, 1268–1269 (2020). - PMC - PubMed
    1. T. Struyf, J. J. Deeks, J. Dinnes, Y. Takwoingi, C. Davenport, M. M. Leeflang, R. Spijker, L. Hooft, D. Emperador, J. Domen, A. Tans, S. Janssens, D. Wickramasinghe, V. Lannoy, S. R. A. Horn, A. Van den Bruel; Cochrane COVID-19 Diagnostic Test Accuracy Group 3 , Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst. Rev. 5, CD013665 (2022). - PMC - PubMed
    1. C. H. Chau, J. D. Strope, W. D. Figg, COVID-19 clinical diagnostics and testing technology. Pharmacotherapy 40, 857–868 (2020). - PMC - PubMed